Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function

Abstract

Objectives: Delgocitinib is a small-molecule JAK inhibitor that has recently been approved in Japan as the world's first topical JAK/STAT pathway inhibitor for the treatment of atopic dermatitis (AD). In this study, the effects of delgocitinib 0.5% ointment treatment on skin rash severity and skin-barrier function were examined. Methods: Adult Japanese patients with mild-moderate AD (n = 23) were recruited into the trial. Healthy subjects (n = 10) were examined in parallel. The effects of four weeks of treatment with delgocitinib 0.5% ointment on the partial eczema area and severity index (pEASI) score, stratum corneum hydration (SCH), and trans-epidermal water-loss (TEWL) were examined. Patient reported effects of the treatment were assessed by a questionnaire. Results: Four weeks of treatment showed a statistically significant improvement (p